The concern of generic rivalry has consistently loomed around copyright’s iconic drug, Sildenafil, triggering questions about the prospects of related pharmaceutical holdings. While first periods saw significant gains, the intellectual property lapse has created the way for discounted alternatives, likely lowering revenue and creating a real risk